Oxytocin to Treat PTSD
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Charleston and San Francisco, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 180 people enrolled
- Started
- 1 Jan 2021
- Ended
- 31 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Oxytocin
- Placebo
- Record updated
- 11 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Veteran
- Any race or ethnicity
- Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of the assessment instruments (> 26 on the Mini Mental Status Exam)
- Meet DSM-5 diagnostic criteria for current (i.e., past 6 months) PTSD (assessed via the CAPS-5); participants may also meet criteria for a mood disorder (except bipolar affective disorder, see Exclusion Criteria); anxiety disorders (e.g. panic disorder, agoraphobia, social phobia, generalized anxiety disorder, or obsessive compulsive disorder)
- Participants taking psychotropic medications will be required to be maintained on a stable dose for at least four weeks before study initiation
Who cannot take part
- Participants on maintenance anxiolytic, antidepressant, or mood stabilizing medications, which have been initiated during the past 4 weeks
- Meeting DSM-5 criteria for a history of or current psychotic or bipolar affective disorders, or with current suicidal or homicidal ideation and intent; those participants will be referred clinically
- Participants who present a serious suicide risk or are likely to require hospitalization during the study
- Pregnancy or breastfeeding for women
Where in United States
- Ralph H. Johnson VA Medical Center, Charleston, SCCharleston, United States
- San Francisco VA Medical Center, San Francisco, CASan Francisco, United States
About the trial
What the trial wants to find out
Posttraumatic stress disorder (PTSD) is a chronic, debilitating condition that disproportionately affects Veterans. Prolonged Exposure (PE) therapy is a "gold standard" treatment for PTSD. However, approximately one-third of Veterans fail to receive an adequate dose of treatment because they prematurely drop out of PE therapy. There is also room to improve PE treatment outcomes. Consistent with the VA Office of Research and Development initiative to develop effective treatments for PTSD, the proposed randomized clinical trial will examine the ability of oxytocin (as compared with placebo) combined with PE to reduce PTSD symptom severity, improve the rate of PTSD symptom reduction, and to enhance PE treatment retention and adherence. This two-site study will leverage the investments made in the nationwide rollout off PE therapy and has the potential to significantly improve mental health care among Veterans, advance the science in this area, and identify mechanisms underlying positive PTSD treatment response. Participants may choose to complete this research study via home-based telemedicine (HBT) care (i.e. service delivery to patients in their homes using consumer friendly, video-conferencing technology). HBT sessions will be delivered via standard desk, laptop computer, tablet, or smartphone using VA approved applications. All procedures that take place via telemedicine will be performed and completed as though they were in-person/in-office
The 2 groups in the trial
- OxytocinTreatment being tested
40 IU intranasal oxytocin
- PlaceboPlacebo, for comparison
intranasal saline spray
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Enhancing Prolonged Exposure Therapy for PTSD With Oxytocin
- Publications
- Enhancing prolonged exposure therapy for PTSD among veterans with oxytocin: Design of a multisite randomized controlled trial.Contemporary clinical trials, 2020
- Record updated
- 11 March 2026